---
schema_version: "secwatch.filing_event.v1"
accession: "0001581280-26-000037"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:54:29.306490+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q2 revenue $110.7M (+19% YoY); raises FY2026 revenue guidance to $442-447M

## Summary
- Record revenue $110.7M, 13th consecutive quarter of sequential growth; gross margin 51.6% (+2 pts YoY).
- DSPS revenue $53.3M (+28% YoY); NGS revenue $57.4M (+12% YoY).
- Net loss $44M ($0.71/share) vs $39.3M ($0.66/share) YoY; adjusted EBITDA loss improved to $13.3M from $14.8M.
- Raised FY2026 revenue guidance to $442-447M; reiterates Q4 FY26 adjusted EBITDA breakeven.
- Booked $7.2M litigation settlement cost for securities class action; entered bispecific licensing with Invenra.

## SEC filing metadata
- accession: 0001581280-26-000037
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000037/0001581280-26-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000037/twist-20260504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001581280-26-000037
- JSON: https://secwatch.observer/filing/0001581280-26-000037.json
- Plain text: https://secwatch.observer/filing/0001581280-26-000037.txt

## Key facts
- Earnings Releases
  Twist Bioscience Corp reported fiscal second quarter 2026 results: revenue $110.7 million, net income $44.0 million, EPS $0.71 per share. Guidance raised.
  - Period: fiscal second quarter 2026
  - Revenue: $110.7 million
  - Net income: $44.0 million
  - EPS: $0.71 per share
  - Guidance: raised
  - Result: reported results
  source text: expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results — Record revenue of $110.7 million in 2QFY26 ; Increase of more than 19% over $92.8 million in 2QFY25; 13th consecutive quarter of sequential growth — — Gross margin of 51.6% in 2QFY26 ; Improvement of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000037/0001581280-26-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.